Browsing Tag
hepatitis D
1 post
Can Norgine turn Vir Biotechnology’s hepatitis D duo into a regional blockbuster? €550m deal signals big bet
Vir Biotechnology licenses its hepatitis D therapy to Norgine in a €550M deal. Find out what this means for commercialization, access, and biotech strategy.